By Josh White
Date: Wednesday 19 Mar 2025
(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a second-line treatment for advanced renal cell carcinoma (RCC) in China had met its primary endpoint of progression-free survival.
Retirement of Independent Non-executive Directors | 20-Mar-2025 | 09:30 | RNS |
2024 Final Results and Business Updates | 19-Mar-2025 | 11:00 | RNS |
Adoption of the 2025 Long Term Incentive Plan | 14-Mar-2025 | 09:30 | RNS |
Vesting of awards under Long Term Incentive Plan | 14-Mar-2025 | 09:30 | RNS |
Notice of Extraordinary General Meeting | 13-Mar-2025 | 09:30 | RNS |
Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
Currency | UK Pounds |
Share Price | 237.00p |
Change Today | 2.00p |
% Change | 0.85 % |
52 Week High | 352.00 |
52 Week Low | 211.00 |
Volume | 67,450 |
Shares Issued | 871.60m |
Market Cap | £2,065.69m |
RiskGrade | 226 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:38 | 500 @ 237.00p |
16:38 | 500 @ 237.00p |
16:38 | 150 @ 237.00p |
16:38 | 500 @ 237.00p |
16:38 | 200 @ 237.00p |
You are here: research